New microneedle patch delivers full dose; Mesothelioma drug delivered via skin; MultiCell, Genisphere partner in RNA arena;

> Researchers at the University of North Carolina at Chapel Hill have developed a microneedle patch with a dissolvable backing that helps deliver a full dose of medication, leaving the needles in place for a longer amount of time. News

> Researchers at Griffith University in Australia are creating a mesothelioma treatment that can be delivered via the skin. More

> MultiCell Technologies and Genisphere are collaborating to develop a targeted nanoparticle treatment for liver cancer. The noncoding double-stranded microRNA is called MCT-485. Release

> Enteris BioPharma launched its business, operational and development arm to extend its recently acquired Peptelligence nasal delivery platform into small molecule therapeutics. Enteris bought the technology from Unigene Laboratories ($UGNE). Release

> Serina Therapeutics has partnered with the Scripps Research Institute to develop polymer-antibody drug conjugates able to deliver a potent cytotoxic agent. More

> Kemwell Biopharma out of Bangalore acquired American CRO and development company Cirrus Pharmaceuticals, which focuses on inhaled, nasal, oral, parenteral, topical and transdermal products. Article

> MedPharm scored a new patent for its MedSpray topical spray-on film for dermatological, topical and transdermal drug delivery. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.